CompletedNCT06796868
A Study to Evaluate Efficacy and Safety of GW117 Tablets in Major Depressive Disorder
Medication studyAges 18–65ChinaDepression
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Baoding and 16 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: July 7, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 280
- Sponsor
- Beijing Greatway Pharmaceutical Technology Co.,Ltd.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- China
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06796868
- Official title
Show the full official title
A Multicenter, Randomized , Double-blind, Parallel, Placebo-controlled Design Clinical Trial of GW117 Tablets
Get this study by email
Recruitment & locations
CompletedBaoding · Beijing · Chengdu
12 more locations
- Chongqing
- Daqing
- Huzhou
- Jilin City
- Mianyang
- Shanghai
- Shenzhen
- Shijiazhuang
- Tianjin
- Wuxi
- Xi'an
- Zhumadian
Questions about this study
Who is behind this study?
The study sponsor is Beijing Greatway Pharmaceutical Technology Co.,Ltd., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including GW117 Tablets and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
